Abstract
Objectives: Safety & efficacy of treprostinil (IV/SQ) in patients with pulmonary fibrosis (PF) and PAH.
Methods: Prospective, open label trial of patients referred for lung transplantation with PF/PAH (mean PA >35 mmHg & PVR >3 WU), treated treprostinil × 12 weeks.
Results: N=14 received treprostinil (18-97 ng/kg/min). The hemodynamics, 6MW, BNP, and UCSD/SF 36 significantly improved. No significant changes were seen in peripheral oxygen at rest or during 6MW.
View this table:
Conclusions: Chronic administration of treprostinil is well tolerated in patients with PF/PAH. Prospective, multicenter, randomized-controlled studies are warranted to verify these results
- © 2011 ERS